uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. SPY

Go back to uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
CARLISLE COMPANIES, Inc. (NYSE: CSL) Delayed: 360.74 -4.98 (1.36%)
Previous Close $365.72    52 Week High $114.49 
Open $361.99    52 Week Low $75.17 
Day High $366.02    P/E 99.93 
Day Low $359.46    EPS $3.61 
Volume 340,849       

(AMEX: CSLLY) Delayed: 31.34 +0.34 (1.10%)
Previous Close $31.00    52 Week High $45.60 
Open $31.15    52 Week Low $33.39 
Day High $31.43    P/E N/A 
Day Low $31.00    EPS $0.00 
Volume 102,987       

UNIQURE (NASDAQ: QURE) Delayed: 49.56 -1.39 (2.73%)
Previous Close $50.95    52 Week High $22.79 
Open $50.83    52 Week Low $6.63 
Day High $51.03    P/E N/A 
Day Low $49.51    EPS $0.00 
Volume 779,427